Recombinant Fibrinogen
The only currently available source of human fibrinogen is plasma from human donor blood. The amount of donated human plasma considered safe is in high demand, and the potential applications of fibrinogen are increasing. Experts believe that this could lead to a shortage of safe plasma-derived fibrinogen in the future.
ProFibrix is committed to establishing a versatile and commercially feasible recombinant production platform for human fibrinogen to enable the development of new, advanced products. The ProFibrix platform is also designed to allow production to be easily scalable to meet any demand.
In collaboration with a large-scale cGMP manufacturer, ProFibrix is currently in the process of expanding the production of recombinant fibrinogen to industrial volumes.
The recombinant fibrinogen platform in development will provide ProFibrix with a unique position in the hemostasis and tissue repair market. The first indication for recombinant fibrinogen may be systemic therapy in patients with inadequate levels of circulating functional fibrinogen.
